<bill session="114" type="s" number="3094" updated="2018-06-02T07:46:48Z">
  <state datetime="2016-06-23">REFERRED</state>
  <status>
    <introduced datetime="2016-06-23"/>
  </status>
  <introduced datetime="2016-06-23"/>
  <titles>
    <title type="short" as="introduced">Price Relief, Innovation, and Competition for Essential Drugs Act</title>
    <title type="short" as="introduced">PRICED Act</title>
    <title type="official" as="introduced">A bill to amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12  to 7 years.</title>
    <title type="display">PRICED Act</title>
  </titles>
  <sponsor bioguide_id="B000944"/>
  <cosponsors>
    <cosponsor bioguide_id="M000303" joined="2016-06-23"/>
  </cosponsors>
  <actions>
    <action datetime="2016-06-23">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2016-06-23" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="114" relation="identical" number="5573"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
  </subjects>
  <amendments/>
  <summary date="2016-06-23T04:00:00Z" status="Introduced in Senate">Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.</summary>
  <committee-reports/>
</bill>
